Lv51
1138 积分 2021-10-19 加入
Targeting the gut microbiota for cancer therapy
9小时前
待确认
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
9小时前
待确认
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities
9小时前
待确认
Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
10小时前
待确认
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2天前
已完结
Lung Cancer
17天前
已完结
Lung cancer screening
17天前
已完结
Evaluating the Patient With a Pulmonary Nodule
17天前
已完结
Squamous cell lung cancer: Current landscape and future therapeutic options
1个月前
已完结
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
1个月前
已完结
皖公网安备34019202002308
